Argenx
ARGX
£456.00
Share price
-0.62%
Change (1 day)
51.03%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
Revenue for Argenx (ARGX)
Revenue in 2024 (TTM): £1.71 Billion
According to Argenx
's latest financial reports the company's current revenue (TTM 
) is £1.65 Billion. an increase over the revenue in the year 2023 that were of £0.96 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Argenx from 2013 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | £1.74 B | 81.32% |
| 2023 | £0.96 B | 183.51% |
| 2022 | £0.33 B | |
| 2019 | £66.84 M | 191.24% |
| 2018 | £22.95 M | -38.28% |
| 2017 | £37.18 M | 168.35% |
| 2016 | £13.85 M | 147.03% |
| 2015 | £5.6 M | 51.05% |
| 2014 | £3.71 M | 23.63% |
| 2013 | £3 M |